These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 28067602)

  • 1. miRNAs in cerebrospinal fluid identify patients with MS and specifically those with lipid-specific oligoclonal IgM bands.
    Quintana E; Ortega FJ; Robles-Cedeño R; Villar ML; Buxó M; Mercader JM; Alvarez-Cermeño JC; Pueyo N; Perkal H; Fernández-Real JM; Ramió-Torrentà L
    Mult Scler; 2017 Nov; 23(13):1716-1726. PubMed ID: 28067602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis.
    Álvarez-Cermeño JC; Muñoz-Negrete FJ; Costa-Frossard L; Sainz de la Maza S; Villar LM; Rebolleda G
    J Neurol Sci; 2016 Jan; 360():41-4. PubMed ID: 26723970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing the presence of oligoclonal IgM bands as a prognostic biomarker of cognitive decline in the early stages of multiple sclerosis.
    Coll-Martinez C; Quintana E; Salavedra-Pont J; Buxó M; González-Del-Rio M; Gómez I; Muñoz-San Martín M; Villar LM; Álvarez-Bravo G; Robles-Cedeño R; Ramió-Torrentà L; Gich J
    Brain Behav; 2021 Dec; 11(12):e2405. PubMed ID: 34796675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.
    Magraner MJ; Bosca I; Simó-Castelló M; García-Martí G; Alberich-Bayarri A; Coret F; Alvarez-Cermeño JC; Martí-Bonmatí L; Villar LM; Casanova B
    Neuroradiology; 2012 Jan; 54(1):5-12. PubMed ID: 21327771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligoclonal IgM bands are a promising biomarker for long-term cognitive outcomes in multiple sclerosis.
    Coll-Martinez C; Quintana E; Buxó M; Salavedra-Pont J; Gasull-Vicens L; Quiroga-Varela A; Costa-Frossard L; Villar LM; Fernández-Díaz E; Gracia J; Aladro Y; Méndez-Burgos A; Cerezo M; Ramió-Torrentà L; Gich J
    Mult Scler Relat Disord; 2022 Dec; 68():104397. PubMed ID: 36544326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome.
    Monreal E; Sainz de la Maza S; Costa-Frossard L; Walo-Delgado P; Zamora J; Fernández-Velasco JI; Villarrubia N; Espiño M; Lourido D; Lapuente P; Toboso I; Álvarez-Cermeño JC; Masjuan J; Villar LM
    Neurol Neuroimmunol Neuroinflamm; 2021 Jul; 8(5):. PubMed ID: 34301819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CSF oligoclonal band patterns reveal disease heterogeneity in multiple sclerosis.
    Villar LM; Masterman T; Casanova B; Gómez-Rial J; Espiño M; Sádaba MC; González-Porqué P; Coret F; Alvarez-Cermeño JC
    J Neuroimmunol; 2009 Jun; 211(1-2):101-4. PubMed ID: 19443047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to interferon in multiple sclerosis is related to lipid-specific oligoclonal IgM bands.
    Bosca I; Villar LM; Coret F; Magraner MJ; Simó-Castelló M; Alvarez-Cermeño JC; Casanova B
    Mult Scler; 2010 Jul; 16(7):810-5. PubMed ID: 20538705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic utility of the IgM oligoclonal bands against myelin lipids in multiple sclerosis.
    Ribes García S; Casanova Estruch B; Gómez Pajares F; Juan Blanco MA
    J Neuroimmunol; 2021 Oct; 359():577698. PubMed ID: 34450374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of oligoclonal IgM specificity in multiple sclerosis disease course.
    Villar L; García-Barragán N; Espiño M; Roldán E; Sádaba M; Gómez-Rial J; González-Porqué P; Alvarez-Cermeño J
    Mult Scler; 2008 Mar; 14(2):183-7. PubMed ID: 17942517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNAs of Human Herpesvirus 6A and 6B in Serum and Cerebrospinal Fluid of Multiple Sclerosis Patients.
    Domínguez-Mozo MI; Nieto-Guerrero A; Pérez-Pérez S; García-Martínez MÁ; Arroyo R; Álvarez-Lafuente R
    Front Immunol; 2020; 11():2142. PubMed ID: 33072077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions.
    Muñoz-San Martín M; Reverter G; Robles-Cedeño R; Buxò M; Ortega FJ; Gómez I; Tomàs-Roig J; Celarain N; Villar LM; Perkal H; Fernández-Real JM; Quintana E; Ramió-Torrentà L
    J Neuroinflammation; 2019 Nov; 16(1):220. PubMed ID: 31727077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?
    Frau J; Villar LM; Sardu C; Secci MA; Schirru L; Ferraro D; Coghe G; Lorefice L; Fenu G; Bedin R; Sola P; Marrosu MG; Cocco E
    J Neurol; 2018 Feb; 265(2):424-430. PubMed ID: 29273846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oligoclonal IgM bands in the cerebrospinal fluid of patients with relapsing MS to inform long-term MS disability.
    Capuano R; Zubizarreta I; Alba-Arbalat S; Sepulveda M; Sola-Valls N; Pulido-Valdeolivas I; Andorra M; Martinez-Heras E; Solana E; Lopez-Soley E; Montejo C; Blanco Y; Fernández-Velasco JI; Gallo A; Bisecco A; Villoslada P; Saiz A; Llufriu S; Villar LM; Martinez-Lapiscina EH
    Mult Scler; 2021 Oct; 27(11):1706-1716. PubMed ID: 33433258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiRNA 106a-5p in cerebrospinal fluid as signature of early relapsing remitting multiple sclerosis: a cross sectional study.
    Zanghì A; Manuti V; Serviddio G; D'Amico E; Avolio C
    Front Immunol; 2023; 14():1226130. PubMed ID: 37711630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder.
    Wan Y; Liu Y; Wang X; Wu J; Liu K; Zhou J; Liu L; Zhang C
    PLoS One; 2015; 10(3):e0121975. PubMed ID: 25763923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis.
    Villar LM; Picón C; Costa-Frossard L; Alenda R; García-Caldentey J; Espiño M; Muriel A; Álvarez-Cermeño JC
    Eur J Neurol; 2015 Aug; 22(8):1169-75. PubMed ID: 25324032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs as biomarkers in progressive multiple sclerosis.
    Vistbakka J; Elovaara I; Lehtimäki T; Hagman S
    Mult Scler; 2017 Mar; 23(3):403-412. PubMed ID: 27246141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS.
    Bruinsma IB; van Dijk M; Bridel C; van de Lisdonk T; Haverkort SQ; Runia TF; Steinman L; Hintzen RQ; Killestein J; Verbeek MM; Teunissen CE; de Jong BA
    J Neuroinflammation; 2017 Dec; 14(1):235. PubMed ID: 29202778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peritoneal fluid modifies the microRNA expression profile in endometrial and endometriotic cells from women with endometriosis.
    Braza-Boïls A; Salloum-Asfar S; Marí-Alexandre J; Arroyo AB; González-Conejero R; Barceló-Molina M; García-Oms J; Vicente V; Estellés A; Gilabert-Estellés J; Martínez C
    Hum Reprod; 2015 Oct; 30(10):2292-302. PubMed ID: 26307093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.